Development and validation of a rapid and sensitive LC-MS/MS method for the determination of aripiprazole in human plasma: Application to a bioequivalence study

Czasopismo : Acta Chromatographica
Tytuł artykułu : Development and validation of a rapid and sensitive LC-MS/MS method for the determination of aripiprazole in human plasma: Application to a bioequivalence study

Autorzy :
Mansoor, S.
Georgia Institute of Technology School of Chemical and Biomolecular Engineering Atlanta GA 30332-0100 USA,
Tas, C.
Georgia Institute of Technology School of Chemical and Biomolecular Engineering Atlanta GA 30332-0100 USA, ctas@gata.edu.tr,
Patel, D. S.
Pramukh Swami Science and H.D. Patel Arts College Chemistry Department Sarva Vidyalaya Campus Kadi 382 715 Gujarat India,
Sharma, N.
BA Research India Ltd. Bio-Analytical Laboratory Bodakdev, Ahmedabad 380054 Gujarat India,
Patel, M. C.
Pramukh Swami Science and H.D. Patel Arts College Chemistry Department Sarva Vidyalaya Campus Kadi 382 715 Gujarat India,
Patel, B. N.
BA Research India Ltd. Bio-Analytical Laboratory Bodakdev, Ahmedabad 380054 Gujarat India, bhavinpatel27@rediffmail.com,
Shrivastav, P. S.
Gujarat University Department of Chemistry, School of Sciences Navrangpura, Ahmedabad 380009 Gujarat India, pranav_shrivastav@yahoo.com,
Sanyal, M.
St. Xavier’s College Department of Chemistry Navrangpura, Ahmedabad 380009 Gujarat India,
Abstrakty : A rapid, selective, and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay has been proposed for the determination of aripiprazole in human plasma. The analyte and propranolol as internal standard (IS) were extracted from 200 μL of human plasma via liquid-liquid extraction using methyl tert-butyl ether under alkaline conditions. The best chromatographic separation was achieved on an Aquasil C18 (100 × 2.1 mm, 5 μm) column using methanol-deionized water containing 2 mM ammonium trifluoroacetate and 0.02% formic acid (65:35, v/v) as the mobile phase under isocratic conditions. Detection of analyte and IS was done by tandem mass spectrometry, operating in positive ion and multiple reaction monitoring (MRM) acquisition mode. The method was fully validated for its selectivity, interference check, sensitivity, carryover check, linearity, precision and accuracy, reinjection reproducibility, recovery, matrix effect, ion suppression/enhancement, stability, ruggedness, and dilution integrity. The assay was linear over the concentration range of 0.10–100 ng mL-1for aripiprazole. The intra-batch and inter-batch precision (%CV) was ≤4.8%, while the mean extraction recovery was >96% for aripiprazole across quality control levels. The method was successfully applied to a bioequivalence study of 10 mg aripiprazole orally disintegrating tablet formulation in 27 healthy Indian subjects under fasting and fed condition. The reproducibility in the measurement of study data was demonstrated by reanalysis of 260 incurred samples.

Słowa kluczowe : aripiprazole, LC-MS/MS, liquid-liquid extraction, human plasma, bioequivalence, incurred sample reanalysis,
Wydawnictwo : University of Silesia in Katowice
Rocznik : 2014
Numer : Vol. 26, no. 2
Strony : 203 – 227
Bibliografia : 1 E. Stip and V. Tourjman, Clin. Ther., 32(Suppl A), S3–S20 (2010)
2 R.S. McIntyre, Clin. Ther., 32(Suppl A), S32–S38 (2010)
3 W.W. Fleischhacker, R.D. McUuade, R.N. Marcus, D. Archibald, R. Swanink, and W.H. Carson, Biol. Psychiatry, 65, 510–517 (2009)
4 A. Deleon, N.C. Patel, and M.L. Crismon, Clin. Ther., 26, 649–666 (2004)
5 Z.A. Sharif and J.A. Lieberman, Aripiprazole. In: A.F. Schatzberg and C.B. Nemeroff (Eds) The American Psychiatric Publishing Textbook of Psychopharmacology, 4th edn, American Psychiatric Publications Inc., Washington DC, 2009, pp. 613–625
6 M.D. Wood, C. Scott, K. Clarke, J. Westaway, C.H. Davies, C. Reavill, M. Hill, C. Rourke, M. Newson, D.N.C. Jones, I.T. Forbes, and A. Gribble, Eur. J. Pharmacol., 546, 88–94 (2006)
7 S.R. Marder, R.D. McQuade, E. Stock, S. Kaplita, R. Marcus, A.Z. Safferman, A.R. Saha, M. Ali, and T. Iwamoto, Schizophr. Res., 61, 123–136 (2003)
8 S.G. Potkin, A.R. Saha, M.J. Kujawa, W.H. Carson, E. Stock, J. Stringfellow, G. Ingenito, and S.R. Marder, Arch. Gen. Psychiatry, 60, 681–690 (2003)
9 ABILIFY (aripiprazole tablets) prescribing information, New York, NY: Bristol-Myers Squibb Company, 2004; and Rockville, Md: Otsuka America Pharmaceutical, Inc., 2004. Available at http://www.abilify.com . Last assessed October 2011
10 S. Mallikaarjun, D.E. Salazaar, and S.L. Bramer, J. Clin. Pharmacol. 44, 179–187 (2004)
11 K.M. Kirschbaum, J. Matthias, M.J. Muller, G. Zernig, A. Saria, A. Mobascher, J. Malevani, and C. Hiemke, Clin. Chem. 51, 1718–1721 (2005)
12 Y. Shimokawa, H. Akiyama, E. Kashiyama, T. Koga, and G.J. Miyanmoto, J. Chromatogr. B, 821, 8–14 (2005)
13 X. Zuo, F. Wang, P. Xu, R. Zhu, and H. Li, Chromatographia, 64, 387–391 (2006)
14 A. Musenga, M.A. Saracino, D. Spinelli, E. Rizzato, G. Boncompagni, E. Kenndler, and M.A. Raggi, Anal. Chim. Acta, 612, 204–211 (2008)
15 S.N. Lin, L. Lamm, T.F. Newton, M.S. Reid, D.E. Moody, and R.L. Foltz, J. Anal. Toxicol., 33, 237–242 (2009)
16 F. Liang, A.V. Terry, and M.G. Bartlett, Biomed. Chromatogr. (2012), doi: 10.1002/bmc.2698
17 M. Caloro, L. Lionetto, I. Cuomo, A. Simonetti, D. Pucci, S.D. Persis, B. Casolla, G.D. Kotzalidis, A. Sciarrette, S.D. Filippis, M. Simmaco, and P. Girardi, J. Pharm. Biomed. Anal., 62, 135–139 (2012)
18 M. Kubo, Y. Mizooka, Y. Hirao, and T. Osumi, J. Chromatogr. B, 822, 294–299 (2005)
19 H.C. Huang, C.H. Liu, T.H. Lan, T.M. Hu, H.J. Chiu, Y.C. Wu, and Y.L. Tseng, J. Chromatogr. B, 856, 57–61 (2007)
20 F. Lancelin, K. Djebrani, K. Tabaouti, L. Kraoul, S. Brovedani, P. Paubel, and M.L. Piketty, J. Chromatogr. B, 867, 15–19 (2008)
21 M. Song, X. Xu, T. Hang, A. Wen, and L. Yang, Anal. Biochem., 385, 270–277 (2009)
22 K.Y. Li, Y.G. Zhou, H.Y. Ren, F. Wang, B.K. Zhang, and H.D. Li, J. Chromatogr. B, 850, 581–585 (2007)
23 C. Waldschmitt, B. Pfuhlmann, and C. Hiemke, Chromatographia, 69, 821–827 (2009)
24 E. Choong, S. Rudaz, A. Kottelat, D. Guillarme, J.L. Veuthey, and C.B. Eap, J. Pharm. Biomed. Anal., 50, 1000–1008 (2009)
25 H. Kirchherr and W.N. Kühn-Velten, J. Chromatogr. B, 843, 100–113 (2006)
26 Guidance for Industry, Bionanlytical Method Validation, US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Centre for Veterinary Medicine (CVM), May 2001
27 B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng, Anal. Chem., 75, 3019–3030 (2003)
28 R. King, R. Bonfiglio, C. Fernandez-Metzler, C. Miller-Stein, and T. Olah, J. Am. Soc. Mass Spectrom., 11, 942–950 (2000)
29 Guidance for Industry: ICH E6 Good Clinical Practice, U.S. Department of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), Centre for Biologics Evaluation and Research (CBER), 1996
30 M. Yadav and P.S. Shrivastav, Bioanalysis, 3, 1007–1024 (2011)
31 M. Kubo, T. Koue, H. Maune, T. Fukuda, and J. Azuma, Drug Metab. Pharmacokinet., 22, 358–366 (2007)
32 X.C. Zuo, S.K. Liu, Z.Y. Yi, Z. Xie, and H.D. Li, Curr. Ther. Res., 67, 258–269 (2006)
DOI :
Cytuj : Mansoor, S. ,Tas, C. ,Patel, D. S. ,Sharma, N. ,Patel, M. C. ,Patel, B. N. ,Shrivastav, P. S. ,Sanyal, M. , Development and validation of a rapid and sensitive LC-MS/MS method for the determination of aripiprazole in human plasma: Application to a bioequivalence study. Acta Chromatographica Vol. 26, no. 2/2014
facebook